1. Home
  2. VWAV vs CRDL Comparison

VWAV vs CRDL Comparison

Compare VWAV & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VWAV

VisionWave Holdings Inc.

HOLD

Current Price

$6.03

Market Cap

135.5M

Sector

Technology

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.52

Market Cap

154.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VWAV
CRDL
Founded
2024
2017
Country
United States
Canada
Employees
12
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.5M
154.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
VWAV
CRDL
Price
$6.03
$1.52
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
570.4K
1.1M
Earning Date
05-18-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.06
$0.88
52 Week High
$15.80
$1.59

Technical Indicators

Market Signals
Indicator
VWAV
CRDL
Relative Strength Index (RSI) 44.95 71.35
Support Level $4.63 $0.95
Resistance Level $8.41 $1.59
Average True Range (ATR) 0.90 0.10
MACD 0.16 0.01
Stochastic Oscillator 39.66 89.36

Price Performance

Historical Comparison
VWAV
CRDL

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: